Baxter To End Watson Ferrlecit Co-Promotion Under FTC Consent Order
A Federal Trade Commission consent order will require Baxter to end its co-marketing agreement with Watson for Ferrlecit in connection with Baxter's acquisition of Wyeth's generic injectable drug business
You may also be interested in...
Baxter is adding about $200 mil. in annual sales to its anesthesia/critical care line via the acquisition of ESI Lederle from Wyeth
Baxter will contribute 80 sales reps to help detail Watson's anemia drug Ferrlecit under a co-promotion agreement-in-principle announced March 14. Baxter's force will double the size of the Ferrlecit sales team; Watson employs 75 Ferrlecit reps. The deal gives Baxter the opportunity to supplement its renal care business with traditional pharmaceuticals. FDA approved the injectable iron product in 1999. Sales were about $140 mil. in 2001...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011